Brief: Galectin Reports Outcome Of Fifth DSMB Meeting For Phase 2B/3 Study Of Belapectin In Patients With Cirrhotic Portal Hypertension
09/04/2024 14:40
April 9 (Reuters) - Galectin Therapeutics Inc GALT.O :
* GALECTIN THERAPEUTICS REPORTS THE POSITIVE OUTCOME OF THE
FIFTH
DATA AND SAFETY MONITORING BOARD MEETING FOR NAVIGATE PHASE 2B/3
STUDY OF BELAPECTIN IN PATIENTS WITH CIRRHOTIC PORTAL
HYPERTENSION CAUSED BY METABOLIC DYSFUNCTION-ASSOCIATED
STEATOHEPATITIS
Source text for Eikon: ID:nGNX6ZPQhZ
Further company coverage: GALT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Galectin Therapeutics
See all newsGalectin Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Galectin Therapeutics Reports June 30, 2026 Financial Results
Galectin Therapeutics Q2 loss widens
Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Galectin Therapeutics rises as FDA clears path for late-stage liver drug study